Alliancebernstein L.P. Reduces Stake in Replimune Group, Inc. (NASDAQ:REPL)

Alliancebernstein L.P. lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 440,612 shares of the company's stock after selling 48,397 shares during the quarter. Alliancebernstein L.P. owned 0.64% of Replimune Group worth $5,336,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sei Investments Co. purchased a new stake in Replimune Group in the fourth quarter valued at $148,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Replimune Group in the fourth quarter worth about $150,000. Arizona State Retirement System acquired a new position in Replimune Group in the fourth quarter valued at approximately $156,000. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after acquiring an additional 6,748 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in Replimune Group in the 4th quarter worth approximately $189,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Price Performance

Shares of NASDAQ:REPL traded up $0.36 during trading on Friday, reaching $7.99. The stock had a trading volume of 651,394 shares, compared to its average volume of 866,398. The business has a fifty day moving average price of $10.75 and a 200-day moving average price of $11.76. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market cap of $615.35 million, a PE ratio of -2.60 and a beta of 1.26. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REPL has been the topic of several recent analyst reports. BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.